Literature DB >> 33641249

Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer.

Kazuhide Ko1, Yoshikazu Kananazawa1, Takeshi Yamada1, Daisuke Kakinuma1, Kunihiko Matsuno1, Fumihiko Ando1, Sho Kuriyama1, Akihisa Matsuda1, Hiroshi Yoshida1.   

Abstract

BACKGROUND: Circulating tumor DNA (ctDNA) detected before surgery disappears after complete surgical resection of the cancer. Residual ctDNA indicates minimal residual disease (MRD), which is a cause of recurrence. The presence of long-fragment circulating cell-free DNA (cfDNA) or methylated cfDNA also implies the presence of cancer. In this study, we evaluated the prognostic value of cfDNA methylation and long-fragment cfDNA concentration in gastric cancer patients undergoing curative surgery
METHODS: Ninety-nine gastric cancer patients were included. Peripheral blood samples were collected before and 1 month after surgery. In patients administered chemotherapy, samples were collected before starting chemotherapy. qPCR was performed to detect long- and short-fragment LINE-1. A plasma HELP (HpaII tiny fragment Enrichment by Ligation-mediated PCR) assay to determine the concentration of HpaII small fragments was performed using ligation-mediated PCR and HpaII was quantified as the HpaII:MspI ratio to detect methylation levels of cfDNA.
RESULTS: Overall survival (OS) of patients with low methylation levels before starting treatment was significantly worse than that of patients with high methylation levels (P = 0.006). In the 90 patients who underwent curative surgery, recurrence-free survival (RFS) and OS of patients with low methylation levels before surgery were worse than those with high methylation levels (P=0.08 and P = 0.11, respectively). RFS and OS of patients with high concentrations of long-fragment LINE-1 after surgery were significantly worse than those with low concentrations of long-fragment LINE-1 (P = 0.009, P = 0.04).
CONCLUSIONS: Pre-surgical low methylation levels of LINE-1 are a negative prognostic factor. Post-surgical high concentrations of long-fragment LINE-1 indicate MRD and a high risk of recurrence.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  LINE-1; biomarker; circulating cell-free DNA; gastric cancer; repeated DNA sequences

Mesh:

Substances:

Year:  2021        PMID: 33641249      PMCID: PMC7957189          DOI: 10.1002/cam4.3755

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  30 in total

Review 1.  Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

Authors:  L Cabel; C Proudhon; P Mariani; D Tzanis; G Beinse; I Bieche; J-Y Pierga; F-C Bidard
Journal:  Eur J Surg Oncol       Date:  2017-01-29       Impact factor: 4.424

2.  Prediction of breast tumor progression by integrity of free circulating DNA in serum.

Authors:  Naoyuki Umetani; Armando E Giuliano; Suzanne H Hiramatsu; Farin Amersi; Taku Nakagawa; Silvana Martino; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2006-09-10       Impact factor: 44.544

3.  Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis.

Authors:  D Takai; Y Yagi; N Habib; T Sugimura; T Ushijima
Journal:  Jpn J Clin Oncol       Date:  2000-07       Impact factor: 3.019

4.  Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis.

Authors:  Keun Hur; Paloma Cejas; Jaime Feliu; Juan Moreno-Rubio; Emilio Burgos; C Richard Boland; Ajay Goel
Journal:  Gut       Date:  2013-05-23       Impact factor: 23.059

5.  Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA.

Authors:  Wang-Yang Pu; Rong Zhang; Li Xiao; Yong-You Wu; Wei Gong; Xiao-Dong Lv; Feng-Yun Zhong; Zhi-Xiang Zhuang; Xu-Ming Bai; Kai Li; Chun-Gen Xing
Journal:  BMC Cancer       Date:  2016-12-09       Impact factor: 4.430

6.  LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.

Authors:  Yuzo Nagai; Eiji Sunami; Yoko Yamamoto; Keisuke Hata; Satoshi Okada; Koji Murono; Koji Yasuda; Kensuke Otani; Takeshi Nishikawa; Toshiaki Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Hiroaki Nozawa; Soichiro Ishihara; Dave S B Hoon; Toshiaki Watanabe
Journal:  Oncotarget       Date:  2017-02-14

Review 7.  Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis.

Authors:  Yunhe Gao; Kecheng Zhang; Hongqing Xi; Aizhen Cai; Xiaosong Wu; Jianxin Cui; Jiyang Li; Zhi Qiao; Bo Wei; Lin Chen
Journal:  Oncotarget       Date:  2017-01-24

8.  Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias.

Authors:  Yutaka Suehiro; Shinichi Hashimoto; Shingo Higaki; Ikuei Fujii; Chieko Suzuki; Tomomi Hoshida; Toshihiko Matsumoto; Yuko Yamaoka; Taro Takami; Isao Sakaida; Takahiro Yamasaki
Journal:  Oncotarget       Date:  2018-03-30

9.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

10.  Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing.

Authors:  Haikun Zhang; Peiling Dong; Shicheng Guo; Chengcheng Tao; Wei Chen; Wenmin Zhao; Jiakang Wang; Ramsey Cheung; Augusto Villanueva; Jian Fan; Huiguo Ding; Steven J Schrodi; Dake Zhang; Changqing Zeng
Journal:  BMC Med       Date:  2020-08-03       Impact factor: 8.775

View more
  3 in total

Review 1.  The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies.

Authors:  Ugur Gezer; Abel J Bronkhorst; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2022-06-01

Review 2.  DNA Methylation: An Important Biomarker and Therapeutic Target for Gastric Cancer.

Authors:  Yunqing Zeng; Huimin Rong; Jianwei Xu; Ruyue Cao; Shuhua Li; Yanjing Gao; Baoquan Cheng; Tao Zhou
Journal:  Front Genet       Date:  2022-03-04       Impact factor: 4.599

Review 3.  Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?

Authors:  Ankur Sheel; Sarah Addison; Surya Pratik Nuguru; Ashish Manne
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.